Arquer Diagnostics Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2006-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.arquerdx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Recruiting
- Conditions
- Bladder Cancer
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Arquer Diagnostics Ltd
- Target Recruit Count
- 650
- Registration Number
- NCT05508568
- Locations
- 🇺🇸
The Urology Center of Colorado, Denver, Colorado, United States
🇺🇸Advanced Urology Institute, Daytona Beach, Florida, United States
🇺🇸First Urology, Jeffersonville, Indiana, United States
Evaluation of MCM5 in Postmenopausal Bleeding Patients
Recruiting
- Conditions
- Endometrial Cancer
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Arquer Diagnostics Ltd
- Target Recruit Count
- 2000
- Registration Number
- NCT05287048
- Locations
- 🇬🇧
Saint Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester, United Kingdom
News
No news found